AbbVie (ABBV) vs. Novartis (NVS)

Company Profile

AbbVie (ABBV) and Novartis (NVS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ABBV is classified in Biotechnology while NVS is classified in Pharmaceuticals.

AbbVie (ABBV) trades as a standard ordinary-equity line, while Novartis (NVS) is an ADR tied to a foreign-share or depositary-receipt structure — compare with FX exposure, program fees, and dividend-withholding-tax differences in mind.

Historical Performance

Historical Performance at a Glance

Profitability

Both AbbVie (ABBV) at 95.59% and Novartis (NVS) at 31.67% rank in the top quartile for Return on Equity (TTM) among industry peers, indicating strong returns on shareholders’ equity.

Novartis (NVS) at 24.06% ranks in the top quartile for Net Profit Margin (TTM), ahead of AbbVie (ABBV) at 6.91%, which sits closer to the industry mid-range.

Both AbbVie (ABBV) at 24.65% and Novartis (NVS) at 30.37% rank in the top quartile for Operating Profit Margin (TTM) among industry peers, indicating both companies convert revenue into operating income more strongly than typical competitors.

Profitability at a Glance

Financial Strength

Both AbbVie (ABBV) at 0.67 and Novartis (NVS) at 0.85 run Current Ratio (MRQ) in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Novartis (NVS) at 1.22 sits in the higher-leverage quartile relative to peers, but AbbVie (ABBV) at 49.22 is higher still, above its industry benchmark range.

Novartis (NVS) at 15.76 ranks in the top quartile for Interest Coverage Ratio (TTM), ahead of AbbVie (ABBV) at 3.46, which sits around the industry mid-range.

Financial Strength at a Glance

Growth

Revenue Growth

Revenue Growth at a Glance

EPS Growth

EPS Growth at a Glance

Dividend

Both AbbVie (ABBV) at 3.11% and Novartis (NVS) at 3.16% report Dividend Yield (TTM) near their industry mid-ranges, so neither company stands out strongly from peers on cash yield relative to share price.

Both AbbVie (ABBV) at 275.84% and Novartis (NVS) at 120.63% report unusual Dividend Payout Ratio (TTM) values — outside the typical 0–100% range, signaling sustainability concerns on both sides.

Dividend at a Glance

Valuation

Novartis (NVS) at 20.29 hovers around the typical industry Price-to-Earnings Ratio (TTM), while AbbVie (ABBV) at 88.76 sits above its industry benchmark range — an elevated trailing earnings multiple for ABBV relative to peers.

Both AbbVie (ABBV) at 6.13 and Novartis (NVS) at 4.88 post Price-to-Sales Ratio (TTM) near the typical industry midpoint — neither company stands out strongly from peers on trailing revenue multiple.

Novartis (NVS) at 8.10 hovers around the typical industry Price-to-Book Ratio (MRQ), while AbbVie (ABBV) at 261.01 sits above its industry benchmark range — an elevated book-value multiple for ABBV relative to peers.

Valuation at a Glance